Int.biotech. Regulatory News (IBT)

Net Assets

£217m

Net Assets per share

579p

Share price

556p

Total value of unquoted investments

£23m

Total number of portfolio companies

90

Dividend

4% of NAV per annum

Company Name

% NAV

Celgene

6.0

Neurocrine

4.2

Biogen

4.2

Array

3.9

Sage

3.8

Genmab

3.8

Adamas

3.7

Regeneron

3.7

Morphosys

3.7

Vertex

3.5

-----------

Total

40.5

Geographical Allocation

% NAV

US & Canada

86

Europe & UK

14

-----------

Total

100

Quoted/Unquoted Allocation

% NAV

Quoted

91

Unquoted

9

-----------

Total

100

NAV % Market Cap

% NAV

Large Cap >USD10BN

35

Mid Cap =USD1-10BN

40

Small Cap

25

-----------

Total

100

NAV % by Therapeutic Areas

% NAV

Oncology

41

CNS

15

Rare diseases

12

Inflammation

6

Ophthalmology

6

Infectious Diseases

4

Metabolic

3

Medtech

2

Other

11

-----------

Total

100